FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results ...
Pharmabiz5h
US FDA grants Fast Track designation to Johnson & Johnson’s nipocalimab to treat adult patients with moderate-to-severe Sjögren’s disease
Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...
Healio20h
Nipocalimab nets FDA fast-track designation for Sjögren’s disease
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Managed Healthcare Executive6d
FDA Approves First Generics of Xarelto
Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...
Hosted on MSN24d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients
SPRING HOUSE, PA — Johnson & Johnson (NYSE ... Administering TREMFYA® 400 mg as SC induction therapy resulted in the following outcomes by Week 12 compared to placebo: Clinical remission ...
Managed Healthcare Executive14d
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.